Approved Sickle Cell Drug Fails to Beat Placebo in Trial
(MedPage Today) -- Crizanlizumab (Adakveo) failed to outperform placebo in patients with sickle cell disease, the phase III STAND trial showed.
Adjusted annualized rate of vaso-occlusive crises leading to healthcare visits was 2.49 with the standard...